Nigatu Abebe from Ethiopia sits on a bed in the Leishmaniasis Research and Treatment Centre (LRTC) at the University of Gondar in Ethiopia. He looks very frail and has been battling against visceral leishmaniasis (VL), also known as kala-azar, and HIV for 11 years.
The results of clinical trials conducted in Ethiopia by DNDi, in partnership with Médecins Sans Frontières, the University of Gondar, and Addis Ababa University, open the way for more effective and safer treatments for people with both HIV and visceral leishmaniasis, a group of patients who have historically suffered from poor treatment options. The results were published today in PLOS Neglected Tropical Diseases.
Bistandsaktuelt[4 January 2019]
“Endelig en pille mot dødelig sovesyke” – “Finally, a pill against deadly sleeping sickness”
“Aprobaron el primer medicamento oral para tratar a una rara enfermedad del sueño que “enloquece” a quienes la padecen” – “They approved the first oral medication to treat a rare sleeping sickness that “maddens” those who suffer from it”